Xeris Biopharma up on positive data from thyroid drug trial

Xeris Biopharma Holdings

20/10/2022 12:00

** Shares of Xeris Biopharma Holdings Inc  XERS.O  up 2.4%
at $1.26 premarket
    ** Co reports positive data from early-stage study of its
experimental drug, XP-8121, compared with standard of care
treatment for hypothyroidism  urn:newsml:reuters.com:*:nBw6zDTD2a
    ** Says data shows weekly dosing of its subcutaneous
injection of XP-8121 provides similar exposure at steady-state
as daily oral standard treatment   
    ** Adds that XP-8121 was generally well-tolerated at all
doses in healthy volunteers 
    ** Says data from the trial supports drug's further
development in patients with congenital or acquired
hypothyroidism who require thyroid hormone replacement
    ** Hypothyroidism happens when thyroid gland doesn't make
enough thyroid hormones to meet body's needs, without which 
many of body's functions may slow down
    ** As of last close, stock down ~58% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))